Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection.

Adam Smith, Isadora Zhang, Phong Trang, Fenyong Liu

Abstract readReview

In one paragraph

Review in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it

0cells of the map it votes in

3citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

Potential Applications of RNase P Ribozyme Against Hepatitis B Virus.Molecules (Basel, Switzerland) · 2025
Review
Perspective on the 65-Year Anniversary of the Discovery of Cytomegalovirus.Viruses · 2025
Article
Development of RNase P ribozyme-based therapy against oral herpesvirus infections by HSV-1 and KSHV.International journal of immunopathology and pharmacology
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Adam SmithProgram in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA.

Isadora ZhangSchool of Public Health, University of California, Berkeley, CA 94720, USA.

Phong TrangSchool of Public Health, University of California, Berkeley, CA 94720, USA.

Fenyong LiuProgram in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA.

Funding

University of California at Berkeley Start-Up Fund 101

6 · The paper itself

Abstract

Nucleic acid-based gene interference and editing strategies, such as antisense oligonucleotides, ribozymes, RNA interference (RNAi), and CRISPR/Cas9 coupled with guide RNAs, are exciting research tools and show great promise for clinical applications in treating various illnesses. RNase P ribozymes have been engineered for therapeutic applications against human viruses such as human cytomegalovirus (HCMV). M1 ribozyme, the catalytic RNA subunit of RNase P from

Indexed as

CytomegalovirusCytomegalovirus InfectionsRibonuclease PRNA, CatalyticAnimalsAntiviral AgentsGenetic EngineeringGenetic TherapyHumansMiceVirus ReplicationAntiviral AgentsRibonuclease PRNA, Catalyticantisenseantiviralscatalytic RNAgene targetingHCMVribozymeRNase P

Identifiers

PMID39205170

DOI10.3390/v16081196

PMCPMC11360822

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.